person Sign In / Create Account

Home

Myeloma News

Dr. Rajkumar's Guide to the Best Myeloma Abstracts for ASH 2019

Posted Nov 12, 2019

Each year over 30,000 doctors, researchers, patient advocates, and patients attend the American Society of Hematology (ASH) conference. To say it is confusing and overwhelming would be an understatement. There are more than 1925 Oral Abstracts and 4039 Poster Abstracts! How does anyone navigate through the maze to make the best use of their time? The Myeloma Crowd has made it a priority to help you with this effort and has asked many of the most skilled and knowledgable myeloma specialists in the world if they would help us in this effort to navigate through the more than 1000 myeloma abstracts to identify those they feel are the most significant.

Dr. Rajkumar has contributed in the past during and after ASH, but has been so kind as to provide his choice of the 5 most significant abstracts prior to the meeting, why he chose them, and when and where ASH visitors can see the oral presentations. Dr. Vincent Rajkumar is Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. His research focuses on clinical, epidemiological, and laboratory research for myeloma and related disorders. Dr. Rajkumar has a great resume, list of accomplishments, and honors that are second to none in the myeloma specialist community. You can view his bio if your click here.

#1 CC-93269, an asymmetric 2-arm humanized IgG T-cell engager that binds bivalently to BCMA and monovalently to CD3ε is highly active in refractory myeloma

Comments: At a >=6mg dose (not yet the maximum tolerated dose) we are seeing a greater than 80% response rate.

Session: 653 Abstract 143 - First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multi-center Trial

Saturday, December 7, 2019: 10:30 AM

Hall E1, Level 2 (Orange County Convention Center)

#2 Two abstracts highlighting problem of racial disparity in myeloma. Blacks much less likely to receive Stem Cell Transplant & Lenalidomide. If access is provided, they have better survival.

Session: 905 Abstract 423 - Racial and Socioeconomic Disparities in the Utilization of Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in the Era of Novel Agents

Sunday, December 8, 2019: 10:00 AM

W314, Level 3 (Orange County Convention Center)

Session: 903 Abstract 383 - Outcomes in Multiple Myeloma Based on Comorbidities and Race

Sunday, December 8, 2019: 8:30 AM

W307, Level 3 (Orange County Convention Center)

#3 Great data showing double & triple hit myeloma has Progression Free Survival of only 2 years despite current therapy and shows we need to target and overcome this early in the disease course.

Session: 731 Abstract 604 - Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Monday, December 9, 2019: 7:45 AM

Sunburst Room (W340) (Orange County Convention Center)

#4 Novel CAR-T targeting both BCMA and CD38. Impressive clinical data already in Phase I. We need these type new approaches for more durable effect from CAR-T.

Session: 653 Abstract 930 - A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Monday, December 9, 2019: 7:30 PM

Valencia A (W415A), Level 4 (Orange County Convention Center)

#5 A great individual patient data meta analysis of auto-auto vs. auto-allo in myeloma. Shows Progression Free Survival and Overall Survival benefit of allo for young patients— but no Overall Survival benefit in high risk patients which is where we have considered using allo.

Session: 732 Abstract 259 - Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up

Saturday, December 7, 2019: 2:00 PM

W307, Level 3 (Orange County Convention Center)

Thank You Dr. Rajkumar for your continued efforts to support the myeloma patient community and your efforts to assist all of us to find the most significant ASH 2019 myeloma abstracts. We will continue to provide this information from other myeloma specialists as their choices become available. Myeloma Crowd hopes this effort will provide an improved ASH 2019 myeloma experience

about the author
Gary Petersen

Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1

#1 CC-93269, an asymmetric 2-arm humanized IgG T-cell engager that binds bivalently to BCMA and monovalently to CD3ε is highly active in refractory myeloma

#2 Two abstracts highlighting problem of racial disparity in myeloma. Blacks much less likely to receive Stem Cell Transplant & Lenalidomide. If access is provided, they have better survival.

#3 Great data showing double & triple hit myeloma has Progression Free Survival of only 2 years despite current therapy and shows we need to target and overcome this early in the disease course.

#4 Novel CAR-T targeting both BCMA and CD38. Impressive clinical data already in Phase I. We need these type new approaches for more durable effect from CAR-T.

#5 A great individual patient data meta analysis of auto-auto vs. auto-allo in myeloma. Shows Progression Free Survival and Overall Survival benefit of allo for young patients— but no Overall Survival benefit in high risk patients which is where we have considered using allo.

More Myeloma News Articles

Thanks to our HealthTree Community for Myeloma Sponsors:

Follow Us

#1 CC-93269, an asymmetric 2-arm humanized IgG T-cell engager that binds bivalently to BCMA and monovalently to CD3ε is highly active in refractory myeloma

#2 Two abstracts highlighting problem of racial disparity in myeloma. Blacks much less likely to receive Stem Cell Transplant & Lenalidomide. If access is provided, they have better survival.

#3 Great data showing double & triple hit myeloma has Progression Free Survival of only 2 years despite current therapy and shows we need to target and overcome this early in the disease course.

#4 Novel CAR-T targeting both BCMA and CD38. Impressive clinical data already in Phase I. We need these type new approaches for more durable effect from CAR-T.

#5 A great individual patient data meta analysis of auto-auto vs. auto-allo in myeloma. Shows Progression Free Survival and Overall Survival benefit of allo for young patients— but no Overall Survival benefit in high risk patients which is where we have considered using allo.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Thanks to our HealthTree Community for Myeloma Sponsors:

Follow Us